Presentation is loading. Please wait.

Presentation is loading. Please wait.

Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment.

Published byΉράκλειτος Αρβανίτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment."— Presentation transcript:

1 Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. C1M, collagen type I MMP-cleaved fragment; C3M, collagen type III MMP-cleaved fragment; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CXCL13, chemokine, CXC motif, ligand 13; MMP, matrix metalloproteinase; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand. *P<0.05 versus placebo; †P<0.01 versus placebo; ‡P<0.0001 versus placebo (χ2 test, unadjusted P values). Cem Gabay et al. RMD Open 2018;4:e000607 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment."

Similar presentations

Correlations of CD68, CD21, CD3, CD20 and CD117 immunohistochemical staining between paired synovial tissue (ST) and colonic mucosa (CM) biopsies of patients.

Correlations of CD68, CD21, CD3, CD20 and CD117 immunohistochemical staining between paired synovial tissue (ST) and colonic mucosa (CM) biopsies of patients.
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.
Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.

Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.
Univariate predictors of (A) ASDAS ID (<1

Univariate predictors of (A) ASDAS ID (<1
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Serum levels of (A), C reactive protein (CRP), (B), erythrocyte sedimentation rate (ESR) and (C), calprotectin of cohort 1 (SPACE) with patients with early.

Serum levels of (A), C reactive protein (CRP), (B), erythrocyte sedimentation rate (ESR) and (C), calprotectin of cohort 1 (SPACE) with patients with early.
Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Similar presentations

Ads by Google